Recent news coverage focuses on Afya's earnings performance, analyst views on stock valuation, and comparisons with peers in the education sector.

• Afya reported Q4 2025 earnings that topped expectations, highlighting continued operational strength and revenue growth [N5].
• Analysts have noted surging earnings estimates for Afya, signaling potential upside in the stock's valuation [N2].
• Wall Street analysts see a 27.62% upside in Afya's stock price, reflecting positive sentiment on the company's growth prospects [N3].
• Comparisons between Afya and competitor LOPE have been discussed, focusing on relative value options for investors [N4].
• Discussions on whether value investors should consider Afya stock have been published, reflecting market interest in the company's fundamentals [N1].
• Afya's Q3 2025 earnings call transcript provides insights into operational execution and strategic priorities [N8].

Afya's diversified education segments and steady revenue growth demonstrate resilience and market demand for medical education in Brazil. The company's ability to increase student enrollment and expand digital offerings supports ongoing revenue expansion. Operational efficiencies have improved gross margins, and investments in marketing and infrastructure aim to enhance brand recognition and service quality. The company's liquidity and cash flow generation provide financial flexibility to pursue acquisitions and innovation. Positive analyst commentary and recent earnings performance indicate market interest in Afya's growth trajectory and business model.

Afya faces risks related to concentration in the Brazilian market and dependence on regulatory and economic conditions affecting education demand and pricing. Rising operating expenses, particularly payroll and marketing costs, could pressure margins if not offset by revenue growth. The increase in finance expenses and debt levels may impact financial flexibility. Changes in tax regulations, such as the Pillar Two Global Minimum Tax, have increased the effective tax rate. Competition in medical education and digital health services could challenge market share. Execution risks include integration of acquisitions and maintaining quality across diverse educational offerings.

Afya's moat is supported by its integrated educational platform spanning undergraduate medical education, continuing medical education, and clinical practice solutions, creating a comprehensive ecosystem for medical professionals. Its scale in Brazil, combined with digital and in-person delivery capabilities, provides competitive advantages in market reach and service breadth. The company's portfolio of trademarks and intellectual property, along with established relationships with healthcare providers and students, further reinforce its market position. Additionally, recurring tuition-based revenue and subscription models contribute to stable cash flows. However, the company operates primarily in one geographic region, which may limit diversification benefits.

• Geographic Concentration Risk: Afya operates primarily in Brazil, exposing it to country-specific economic, regulatory, and political risks that could impact demand for its educational services.
• Cost and Margin Pressure: Increasing payroll, marketing, and depreciation expenses may pressure operating margins if revenue growth does not keep pace.
• Debt and Finance Expense: The company has significant loans and financing obligations, with rising finance expenses that could affect liquidity and financial flexibility.
• Regulatory and Tax Changes: Changes in tax laws, including the Pillar Two Global Minimum Tax, have increased the effective tax rate, potentially impacting net income.
• Competitive Environment: Competition in medical education and digital health solutions may affect Afya's market share and pricing power.

• Afya Ltd operates primarily in Brazil and reports in Brazilian Real (BRL).
• The company has three operating segments: Undergraduate education, Continuing Education, and Medical Practice Solutions.
• Undergraduate segment provides educational services through undergraduate courses related to medical school, health sciences, and other ex-health undergraduate programs.
• Continuing Education segment offers medical education including residency preparation, specialization test preparation, and graduate courses in medicine, delivered via digital and in-person content.
• Medical Practice Solutions segment provides clinical decision, clinical management, and doctor-patient relationship services for physicians and healthcare players.
• Revenue primarily comes from tuition fees for medical and other undergraduate and graduate courses, student fees, education-related activities, digital content, and digital service subscriptions.
• For the fiscal year ended December 31, 2025, revenue was BRL 3,697.3 million, an 11.9% increase from 2024.
• Net income for 2025 was BRL 768.4 million, an 18.4% increase from 2024.
• Basic earnings per share for 2025 were BRL 8.32, diluted EPS was BRL 8.24.
• Cost of services was 35.5% of revenue in 2025, down from 36.8% in 2024, indicating improved cost efficiency.
• Operating income increased 19.9% year-over-year to BRL 1,213.1 million in 2025.
• Selling, general and administrative expenses increased 10.4% in 2025, driven by payroll, marketing, and depreciation expenses.
• The company had cash and cash equivalents of BRL 1,125.4 million as of December 31, 2025, with a current ratio of 2.2 and a cash ratio of 1.27, indicating solid liquidity.
• Loans and financing totaled approximately BRL 2,054.3 million as of December 31, 2025, with various maturities and interest rates.
• The company generated net cash from operating activities of BRL 1,531.6 million in 2025, up from BRL 1,432.7 million in 2024.
• Capital expenditures were BRL 364.0 million in 2025, mainly for acquisitions, campus expansion, and development of new solutions.
• Afya has a workforce of 9,395 employees as of December 31, 2025, with the majority based in Brazil.
• The company has trademark registrations and pending applications in Brazil, the US, Mexico, the EU, and Portugal.
• Afya's revenue growth in 2025 was driven by organic growth in medical school seats, consolidation of acquisitions, and increased student numbers across segments.
• The Medical Practice Solutions segment revenue increased 5.9% in 2025, with a slight increase in active paying users and price adjustments.
• The company has a related party transaction policy and discloses related party transactions.
• Afya's effective tax rate increased to 10.7% in 2025 from 4.1% in 2024, partly due to the Pillar Two Global Minimum Tax effects.